Baird analyst Joel Beatty raised the firm’s price target on PTC Therapeutics (PTCT) to $52 from $48 and keeps an Outperform rating on the shares. The firm said they are positive on the shares after a KOL earlier today after Friedreich’s ataxia; separately, they believe the phase 2 failure of utreloxastat in ALS announced after the close should have little impact on the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics to sell Priority Review Voucher for $150M
- PTC Therapeutics: Phase 2 CardinALS study did not meet its primary endpoint
- PTC Therapeutics price target raised to $62 from $51 at JPMorgan
- PTC Therapeutics price target raised to $45 from $43 at Barclays
- PTC Therapeutics’ AADC deficiency gene therapy granted FDA approval